-
DRAGON: Determining Regulatory Associations using Graphical models on multi-Omic Networks
Authors:
Katherine H. Shutta,
Deborah Weighill,
Rebekka Burkholz,
Marouen Ben Guebila,
Dawn L. DeMeo,
Helena U. Zacharias,
John Quackenbush,
Michael Altenbuchinger
Abstract:
The increasing quantity of multi-omics data, such as methylomic and transcriptomic profiles, collected on the same specimen, or even on the same cell, provide a unique opportunity to explore the complex interactions that define cell phenotype and govern cellular responses to perturbations. We propose a network approach based on Gaussian Graphical Models (GGMs) that facilitates the joint analysis o…
▽ More
The increasing quantity of multi-omics data, such as methylomic and transcriptomic profiles, collected on the same specimen, or even on the same cell, provide a unique opportunity to explore the complex interactions that define cell phenotype and govern cellular responses to perturbations. We propose a network approach based on Gaussian Graphical Models (GGMs) that facilitates the joint analysis of paired omics data. This method, called DRAGON (Determining Regulatory Associations using Graphical models on multi-Omic Networks), calibrates its parameters to achieve an optimal trade-off between the network's complexity and estimation accuracy, while explicitly accounting for the characteristics of each of the assessed omics "layers." In simulation studies, we show that DRAGON adapts to edge density and feature size differences between omics layers, improving model inference and edge recovery compared to state-of-the-art methods. We further demonstrate in an analysis of joint transcriptome - methylome data from TCGA breast cancer specimens that DRAGON can identify key molecular mechanisms such as gene regulation via promoter methylation. In particular, we identify Transcription Factor AP-2 Beta (TFAP2B) as a potential multi-omic biomarker for basal-type breast cancer. DRAGON is available as open-source code in Python through the Network Zoo package (netZooPy v0.8; netzoo.github.io).
△ Less
Submitted 21 September, 2022; v1 submitted 4 April, 2021;
originally announced April 2021.
-
Identification and Development of Therapeutics for COVID-19
Authors:
Halie M. Rando,
Nils Wellhausen,
Soumita Ghosh,
Alexandra J. Lee,
Anna Ada Dattoli,
Fengling Hu,
James Brian Byrd,
Diane N. Rafizadeh,
Ronan Lordan,
Yanjun Qi,
Yuchen Sun,
Christian Brueffer,
Jeffrey M. Field,
Marouen Ben Guebila,
Nafisa M. Jadavji,
Ashwin N. Skelly,
Bharath Ramsundar,
**hui Wang,
Rishi Raj Goel,
YoSon Park,
the COVID-19 Review Consortium,
Simina M. Boca,
Anthony Gitter,
Casey S. Greene
Abstract:
After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavir…
▽ More
After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a closely related species of SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Both of these previous epidemics were controlled fairly rapidly through public health measures, and no vaccines or robust therapeutic interventions were identified. However, previous insights into the immune response to coronaviruses gained during the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) have proved beneficial to identifying approaches to the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). A number of potential therapeutics against SARS-CoV-2 and the resultant COVID-19 illness were rapidly identified, leading to a large number of clinical trials investigating a variety of possible therapeutic approaches being initiated early on in the pandemic. As a result, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA) in the United States, and many other therapeutics remain under investigation. Here, we describe a range of approaches for the treatment of COVID-19, along with their proposed mechanisms of action and the current status of clinical investigation into each candidate. The status of these investigations will continue to evolve, and this review will be updated as progress is made.
△ Less
Submitted 10 September, 2021; v1 submitted 3 March, 2021;
originally announced March 2021.
-
Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure
Authors:
Halie M. Rando,
Adam L. MacLean,
Alexandra J. Lee,
Ronan Lordan,
Sandipan Ray,
Vikas Bansal,
Ashwin N. Skelly,
Elizabeth Sell,
John J. Dziak,
Lamonica Shinholster,
Lucy D'Agostino McGowan,
Marouen Ben Guebila,
Nils Wellhausen,
Sergey Knyazev,
Simina M. Boca,
Stephen Capone,
Yanjun Qi,
YoSon Park,
Yuchen Sun,
David Mai,
Joel D. Boerckel,
Christian Brueffer,
James Brian Byrd,
Jeremy P. Kamil,
**hui Wang
, et al. (9 additional authors not shown)
Abstract:
The novel coronavirus SARS-CoV-2, which emerged in late 2019, has since spread around the world and infected hundreds of millions of people with coronavirus disease 2019 (COVID-19). While this viral species was unknown prior to January 2020, its similarity to other coronaviruses that infect humans has allowed for rapid insight into the mechanisms that it uses to infect human hosts, as well as the…
▽ More
The novel coronavirus SARS-CoV-2, which emerged in late 2019, has since spread around the world and infected hundreds of millions of people with coronavirus disease 2019 (COVID-19). While this viral species was unknown prior to January 2020, its similarity to other coronaviruses that infect humans has allowed for rapid insight into the mechanisms that it uses to infect human hosts, as well as the ways in which the human immune system can respond. Here, we contextualize SARS-CoV-2 among other coronaviruses and identify what is known and what can be inferred about its behavior once inside a human host. Because the genomic content of coronaviruses, which specifies the virus's structure, is highly conserved, early genomic analysis provided a significant head start in predicting viral pathogenesis and in understanding potential differences among variants. The pathogenesis of the virus offers insights into symptomatology, transmission, and individual susceptibility. Additionally, prior research into interactions between the human immune system and coronaviruses has identified how these viruses can evade the immune system's protective mechanisms. We also explore systems-level research into the regulatory and proteomic effects of SARS-CoV-2 infection and the immune response. Understanding the structure and behavior of the virus serves to contextualize the many facets of the COVID-19 pandemic and can influence efforts to control the virus and treat the disease.
△ Less
Submitted 3 December, 2021; v1 submitted 1 February, 2021;
originally announced February 2021.
-
Gene targeting in disease networks
Authors:
Deborah Weighill,
Marouen Ben Guebila,
Kimberly Glass,
John Platig,
Jen Jen Yeh,
John Quackenbush
Abstract:
Profiling of whole transcriptomes has become a cornerstone of molecular biology and an invaluable tool for the characterization of clinical phenotypes and the identification of disease subtypes. Analyses of these data are becoming ever more sophisticated as we move beyond simple comparisons to consider networks of higher-order interactions and associations. Gene regulatory networks model the regul…
▽ More
Profiling of whole transcriptomes has become a cornerstone of molecular biology and an invaluable tool for the characterization of clinical phenotypes and the identification of disease subtypes. Analyses of these data are becoming ever more sophisticated as we move beyond simple comparisons to consider networks of higher-order interactions and associations. Gene regulatory networks model the regulatory relationships of transcription factors and genes and have allowed the identification of differentially regulated processes in disease systems. In this perspective we discuss gene targeting scores, which measure changes in inferred regulatory network interactions, and their use in identifying disease-relevant processes. In addition, we present an example analysis or pancreatic ductal adenocarcinoma demonstrating the power of gene targeting scores to identify differential processes between complex phenotypes; processes which would have been missed by only performing differential expression analysis. This example demonstrates that gene targeting scores are an invaluable addition to gene expression analysis in the characterization of diseases and other complex phenotypes.
△ Less
Submitted 11 January, 2021;
originally announced January 2021.
-
Creation and analysis of biochemical constraint-based models: the COBRA Toolbox v3.0
Authors:
Laurent Heirendt,
Sylvain Arreckx,
Thomas Pfau,
Sebastián N. Mendoza,
Anne Richelle,
Almut Heinken,
Hulda S. Haraldsdóttir,
Jacek Wachowiak,
Sarah M. Keating,
Vanja Vlasov,
Stefania Magnusdóttir,
Chiam Yu Ng,
German Preciat,
Alise Žagare,
Siu H. J. Chan,
Maike K. Aurich,
Catherine M. Clancy,
Jennifer Modamio,
John T. Sauls,
Alberto Noronha,
Aarash Bordbar,
Benjamin Cousins,
Diana C. El Assal,
Luis V. Valcarcel,
Iñigo Apaolaza
, et al. (30 additional authors not shown)
Abstract:
COnstraint-Based Reconstruction and Analysis (COBRA) provides a molecular mechanistic framework for integrative analysis of experimental data and quantitative prediction of physicochemically and biochemically feasible phenotypic states. The COBRA Toolbox is a comprehensive software suite of interoperable COBRA methods. It has found widespread applications in biology, biomedicine, and biotechnology…
▽ More
COnstraint-Based Reconstruction and Analysis (COBRA) provides a molecular mechanistic framework for integrative analysis of experimental data and quantitative prediction of physicochemically and biochemically feasible phenotypic states. The COBRA Toolbox is a comprehensive software suite of interoperable COBRA methods. It has found widespread applications in biology, biomedicine, and biotechnology because its functions can be flexibly combined to implement tailored COBRA protocols for any biochemical network. Version 3.0 includes new methods for quality controlled reconstruction, modelling, topological analysis, strain and experimental design, network visualisation as well as network integration of chemoinformatic, metabolomic, transcriptomic, proteomic, and thermochemical data. New multi-lingual code integration also enables an expansion in COBRA application scope via high-precision, high-performance, and nonlinear numerical optimisation solvers for multi-scale, multi-cellular and reaction kinetic modelling, respectively. This protocol can be adapted for the generation and analysis of a constraint-based model in a wide variety of molecular systems biology scenarios. This protocol is an update to the COBRA Toolbox 1.0 and 2.0. The COBRA Toolbox 3.0 provides an unparalleled depth of constraint-based reconstruction and analysis methods.
△ Less
Submitted 23 February, 2018; v1 submitted 11 October, 2017;
originally announced October 2017.
-
Toward a closed-loop subcutaneous delivery of L-DOPA
Authors:
Marouen Ben Guebila,
Johan Thunberg
Abstract:
L-DOPA has been the gold standard treatment for Parkinson's disease since 50 years. Being the direct biochemical precursor of dopamine, L-DOPA is effectively converted in the brain, but two major phenomena reduce its therapeutic action: i) competition with amino acids in the gut wall and in the blood brain barrier and ii) its fast kinetics (absorption, distribution, metabolism, and elimination). C…
▽ More
L-DOPA has been the gold standard treatment for Parkinson's disease since 50 years. Being the direct biochemical precursor of dopamine, L-DOPA is effectively converted in the brain, but two major phenomena reduce its therapeutic action: i) competition with amino acids in the gut wall and in the blood brain barrier and ii) its fast kinetics (absorption, distribution, metabolism, and elimination). Continuous administration of L-DOPA, such as jejunal pumps, have addressed the issue of fast absorption. Considering a subcutaneous delivery of L-DOPA allows to bypass the gastrointestinal tract and avoid competition with dietary amino acids. Remains the competition at the blood barrier between amino acids and L-DOPA, which we address by proposing a closed-loop controlled, continuous subcutaneous delivery pump. In the proof-of-concept format, the delivery strategy evaluated on comprehensive model of L-DOPA kinetics, holds the promise of improving the treatment of late-stage Parkinson's disease patients.
△ Less
Submitted 24 August, 2016;
originally announced August 2016.